Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.
Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
StandardStandard
Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease. / Hughes, D.; Hughes, D.A.; Bodger, K. et al.
2008. Papur a gyflwynwyd yn Clinical Pharmacology Colloquium, Bangor University, Wales, UK.
2008. Papur a gyflwynwyd yn Clinical Pharmacology Colloquium, Bangor University, Wales, UK.
Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
HarvardHarvard
Hughes, D, Hughes, DA, Bodger, K & Kikuchi, T 2008, 'Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.', Papur a gyflwynwyd yn Clinical Pharmacology Colloquium, Bangor University, Wales, UK, 3/01/01.
APA
Hughes, D., Hughes, D. A., Bodger, K., & Kikuchi, T. (2008). Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.. Papur a gyflwynwyd yn Clinical Pharmacology Colloquium, Bangor University, Wales, UK.
CBE
Hughes D, Hughes DA, Bodger K, Kikuchi T. 2008. Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease. Papur a gyflwynwyd yn Clinical Pharmacology Colloquium, Bangor University, Wales, UK.
MLA
Hughes, D. et al. Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.. Clinical Pharmacology Colloquium, Bangor University, Wales, UK, 03 Ion 0001, Papur, 2008.
VancouverVancouver
Hughes D, Hughes DA, Bodger K, Kikuchi T. Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.. 2008. Papur a gyflwynwyd yn Clinical Pharmacology Colloquium, Bangor University, Wales, UK.
Author
RIS
TY - CONF
T1 - Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.
AU - Hughes, D.
AU - Hughes, D.A.
AU - Bodger, K.
AU - Kikuchi, T.
PY - 2008/4/1
Y1 - 2008/4/1
M3 - Paper
T2 - Clinical Pharmacology Colloquium, Bangor University, Wales, UK
Y2 - 3 January 0001
ER -